|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01244 3D MEDICINES
Nominal 
3.570 +0.150 (+4.386%) | 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 445,647 | -29.814% | 634,949 | 567,392 | 60,260 | 0 |
| Cost of Sales | (36,572) | -25.502% | (49,091) | (42,215) | (4,277) | -- |
| Gross Profit | 409,075 | -30.175% | 585,858 | 525,177 | 55,983 | -- |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (10,057) | -- | 837 | (658,330) | (954,872) | (319,232) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | (199,378) | -64.553% | (562,466) | (1,052,030) | (1,461,825) | (635,380) | |
| Taxation | 0 | -- | (55) | 0 | 0 | 0 | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 16,715 | -55.808% | 37,824 | 27,680 | 27,733 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (182,663) | -65.187% | (524,697) | (1,024,350) | (1,434,092) | (635,380) | |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (1,420) | -- | 1,241 | (4,097) | (3,974) | 6,448 |
| Depreciation & Amortisation | 25,251 | -0.825% | 25,461 | 21,600 | 12,591 | 3,371 |
| Directors' Emoluments | -- | -- | 288,558 | 104,379 | 79,673 | 1,300 |
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | Unqualified (Modified Report) | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | -75.000 | -67.391% | -230.000 | -2,252.000 | -3,672.000 | -- |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | -- | -- |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | (0.632) | (6.129) | (9.656) | -- |
| NBV per share ($) | 3.040 | -- | 3.628 | 3.689 | -- | -- |
| Remarks: | Real time quote last updated: 17/04/2025 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (¥) | RMB -182,663,000 |
| %Change | -65.187% |
| EPS / (LPS) | RMB -0.750 |
| NBV Per Share (¥) | RMB 3.040 |